SLC3037
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases[1].
Product Specifications
UNSPSC
12352005
Target
NEKs; NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/slc3037.html
Concentration
10mM
Purity
99.85
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
CN(CCNC(C1=CC(C2=CSC3=C2N=C(N=C3)NC4=CC=C(C=C4)N5CCN(CC5)CC)=CC=C1)=O)C
Molecular Formula
C29H35N7OS
Molecular Weight
529.70
References & Citations
[1]Park K, et al. A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout. Front Immunol. 2024 Feb 2;14:1307739.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NEK7; NLRP3
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CDH11 (Cadherin 11, Type 2, OB-Cadherin (Osteoblast), CAD11, CDHOB, OB, OSF-4) (MaxLight 750)
CDH11 (Cadherin 11, Type 2, OB-Cadherin (Osteoblast), CAD11, CDHOB, OB, OSF-4) (MaxLight 750)
